Cargando…
Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model
Vascular endothelial growth factor (VEGF) inhibition by the addition of bevacizumab to the chemotherapy regimen of metastatic colorectal cancer leads to an improved outcome. However, anti-angiogenic tumor therapy targeting a single factor may be limited by complementary mechanisms. Angiopoietin-2 (A...
Autores principales: | Mueller, Thomas, Freystein, Juana, Lucas, Henrike, Schmoll, Hans-Joachim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719918/ https://www.ncbi.nlm.nih.gov/pubmed/31394786 http://dx.doi.org/10.3390/molecules24162865 |
Ejemplares similares
-
Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis
por: Kanakaraj, Palanisamy, et al.
Publicado: (2012) -
Differential Effects of Ang-2/VEGF-A Inhibiting Antibodies in Combination with Radio- or Chemotherapy in Glioma
por: Solecki, Gergely, et al.
Publicado: (2019) -
Preclinical Efficacy and Safety of an Anti-Human VEGFA and Anti-Human NRP1 Dual-Targeting Bispecific Antibody (IDB0076)
por: Ko, Jong-Hee, et al.
Publicado: (2020) -
Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence
por: Luetzkendorf, Jana, et al.
Publicado: (2010) -
ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models
por: Yeom, Dong-Hoon, et al.
Publicado: (2020)